Actively Recruiting
Intravenous Neonatal Central Access Safety Trial
Led by University of Turin, Italy · Updated on 2026-03-30
736
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
Sponsors
U
University of Turin, Italy
Lead Sponsor
P
Pall Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Particulate contamination due to infusion therapy (administration of parenteral nutrition and medications) carries a potential health risk for infants in neonatal intensive care units (NICU). In-line filtration is increasingly used in critically-ill infants but its benefits, by preventing micro-particle infusion in neonates, remain to be demonstrated. In-line filters in the intravenous administration sets prevent the infusion of particles, which may reduce infectious complications.
CONDITIONS
Official Title
Intravenous Neonatal Central Access Safety Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients admitted to NICU with at least one central venous catheter
You will not qualify if you...
- Patients with peripheral venous catheter
- Patients with inflammatory episode at the time of enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Città della Salute e della Scienza
Torino, Italia, Italy, 10100
Actively Recruiting
Research Team
F
Francesco Cresi, PhD MD
CONTACT
E
Elena Maggiora, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here